Drug Trial Radar · NCT02124512
Blood Lipopolysaccharide (LPS) Rifaximin Study
Last checked: Nov 20, 2026Latest source record: Aug 21, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
12
Actual
Start
Mar 2015
Primary completion
May 31, 2019
Study completion May 31, 2019
Sponsor
- Lead sponsor
- Philip KernAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- First posted
- Apr 28, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 35 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Metabolic syndrome is a condition involving elevated levels of fat in the blood, a tendency towards diabetes, hypertension, and too much fat around the abdomen (an increased waistline). Individuals with metabolic syndrome often have impaired glucose tolerance, which is a condition where blood sugar is normal when fasting (before eating), but is too high after drinking a sugary drink. This is due to an abnormality in the body's sensitivity to insulin (insulin resistance), which is due in part to an inability of the muscle to take up glucose. People with metabolic syndrome have inflammation in their fat tissue and in their blood stream, and the changes in the level of inflammatory chemicals produced by cells in your fat tissues will be studied. One possible source of the inflammation may be the bacteria in the intestine. When individuals eat fatty foods, some of the bacterial products become attached to the fat in their blood and then get directed to fat tissue. The investigators wish to determine whether individuals have an excessive amount of inflammation in their fat tissues, and whether this inflammation comes from the bacteria in their intestines. To determine this, the investigators wish to treat individuals with an antibiotic that reduces the bacteria in their intestines and in their blood, and determine whether this reduces their overall level of inflammation.
Conditions
- Obese
- Insulin Resistance
- Metabolic Syndrome
Interventions
Rifaximin SSDDrug
Study Drug dosing will be 80 mg SSD once daily
PlaceboOther
80 mg placebo once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Circulating LPSTime frame: 0, 4 and 8 hours at Baseline, and 0, 4 and 8 hours after 12 weeks of treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Kentucky Center for Clinical and Translational Science
Lexington, Kentucky
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.